Home > About GAMMAGARD LIQUID > GAMMAGARD LIQUID IV

GAMMAGARD LIQUID IV

Intravenous (IV) Administration


Sustained Protection Against Infection1,2

In a clinical study of IV administration of GAMMAGARD LIQUID treatment:


There were no cases of validated acute serious bacterial
infections observed

No patients were hospitalized due to validated bacterial infections

There were four cases of validated other bacterial infections observed
(1 urinary tract infection, 1 gastroenteritis, 2 otitis media)

  • In clinical studies, 15 side effects in 8 subjects were serious. Two serious reactions occured (two episodes of aseptic meningitis in one patient).

Demonstrated Tolerability by Patients on IV Administration

(381/400) of the side effects reported in this study
were considered mild (217) to moderate (164). The remaining 5% of the side effects (19/400) were rated severe.1

Mild side effects were defined as transient discomfort that resolves spontaneously or with minimal intervention.

Moderate side effects were defined as limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae.

Severe side effects were defined as marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae.

Please see below for Detailed Important Risk Information.

GAMMAGARD LIQUID is formulated with1:

  • Added Sugars1
  • Added Sodium1
  • Added Preservatives1
  • Added Proline1

  • Stabilized and buffered with glycine for those patients in whom these additives may be a concern1
  • The packaging is not made with natural rubber latex1

GAMMAGARD LIQUID Brochure

To learn more about PI and treatment with GAMMAGARD LIQUID treatment, both IV and SubQ, you can download the brochure from our Additional Resources page.

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [package insert]. Westlake Village, CA: Baxter Healthcare Corporation. 2. Church JA, Leibl H, Stein MR, et al; and the US-PID-IGIV 10% Study Group. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26(4):388-395.

    

  • Sign up to get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Enroll Now
  • 
  • Ask an Advocate Questions about PI or PI treatments? Our trained Patient and Nurse Advocates can help, and asking your question is easy with our Ask An Advocate feature.
    Start Getting Answers
  • 
  • My Infusion Log & Wellness Calendar Stay on top of your treatment and overall wellness by logging your infusions after every treatment, tracking your daily health, and communicating this information to your healthcare team.
    See More Resources

You are now leaving GAMMAGARD.com

Shire is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the GAMMAGARD.com site. A link to other web sites does not constitute an endorsement of Shire of the linked site, its products or services.

The browser window or tab for GAMMAGARD.com will remain open underneath the new browser window or tab. To return to GAMMAGARD.com at any time, close this tab or window.

Return to
GAMMAGARD.com
Continue

Terms and Conditions

Patient instructions

  1. By using this coupon, you are certifying that:
  2. 1) You meet the eligibility criteria and have read and agree to the terms and conditions of this manufacturer coupon program;
  3. 2) You will not, at any time, submit any costs for the product dispensed pursuant to this coupon to any government healthcare program for reimbursement;
  4. 3) You are permitting your personal information, including name, address, phone number, email address, and information related to health insurance and treatment, to be shared with Shire and companies working with Shire for the purpose of administering this program; and
  5. 4) You will notify your health insurance provider or other third-party payer of the use of this coupon if required to do so.
  6. If your insurance situation changes it is your responsibility to notify Shire's MyIgCoPayCard program.
  7. For questions about this program, patients and caregivers can call MyIgSource at (855) 250-5111.

Pharmacy instructions

  1. By submitting a claim for reimbursement pursuant to this manufacturer coupon program, the Pharmacy represents and warrants that:
  2. 1) It has dispensed GAMMAGARD LIQUID treatment to an eligible patient and in accordance with the terms and conditions of this program and the accompanying prescription;
  3. 2) Its participation in this program is consistent with all applicable laws and any obligations, including its contract with the applicable payer;
  4. 3) If the patient's insurance situation changes, it will notify Shire immediately by contacting the MyIgCoPayCard program;
  5. 4) It will report coupon assistance received to payers if so required; and
  6. 5) The entire benefit amount received will go to eligible expenses and it will not retain any portion of the benefit as payment to it for administration or ineligible expenses.
  7. For questions regarding processing, claim transmission, patient eligibility, or other issues, pharmacists can call the MyIgCoPayCard program directly at (855) 217-1615.